37. Generalised pustular psoriasis Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 79 Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102

Drugs and their primary sponsors and trial info
AIN457   
   NOVARTIS FARMA S.p.A.
      2014   Phase 3   EUCTR2013-003086-34-IT   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
   Novartis Farmacéutica, S.A.
      2013   Phase 3   EUCTR2013-003086-34-ES   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-JapicCTI-132305   -
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-003086-34-PL   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
      2014   Phase 3   EUCTR2013-003086-34-BE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
      2013   Phase 3   EUCTR2013-003086-34-SE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
      2013   Phase 3   EUCTR2013-003086-34-GB   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
      2013   Phase 3   EUCTR2013-003086-34-AT   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
AIN457,   
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2013-003086-34-DE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
ANB019   
   AnaptysBio Inc.
      2022   Phase 3   EUCTR2021-001448-90-FR   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
      2022   Phase 3   EUCTR2021-001448-90-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
      2022   Phase 3   EUCTR2021-001447-27-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
      2021   Phase 3   EUCTR2021-001448-90-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-001447-27-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004021-33-GB   United Kingdom;United States;
   AnaptysBio, Inc.
      2019   Phase 2   NCT03619902   Korea, Republic of;Poland;United Kingdom;United States;
Acitretin   
   Department of Dermatology, Children's Hospital of Chongqing Medical University
      2021   Phase 0   ChiCTR2100044690   China;
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003542   China;
   Shanghai Dermatology Hospital
      2020   Phase 0   ChiCTR2000037099   China;
Adalimumab   
   AbbVie
      2015   Phase 3   NCT02533375   Japan;
Alefacept   
   The Guenther Dermatology Research Centre
      2005   Phase 2   NCT00301002   Canada;
Alvarez 2   
   AnaptysBio Inc.
      2018   Phase 2   EUCTR2017-004021-33-GB   United Kingdom;United States;
Anakinra   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2013   Phase 2   NCT01794117   United States;
Anti-IL-36R monoclonal antibody   
   AnaptysBio Inc.
      2022   Phase 3   EUCTR2021-001448-90-FR   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
      2022   Phase 3   EUCTR2021-001448-90-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
      2022   Phase 3   EUCTR2021-001447-27-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand;
      2021   Phase 3   EUCTR2021-001448-90-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-001447-27-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004021-33-GB   United Kingdom;United States;
BI 655130   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2018-003081-14-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2018-003081-14-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2018-003081-14-GR   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2018-003080-56-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim España, S.A.
      2020   Phase 2   EUCTR2018-003081-14-ES   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim France
      2020   Phase 2   EUCTR2018-003081-14-FR   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
      2019   Phase 3   EUCTR2018-003080-56-FR   Australia;China;France;Germany;Greece;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
      2019   Phase 2   EUCTR2017-004231-37-FR   France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
   Boehringer Ingelheim Netherlands BV
      2020   Phase 2   EUCTR2018-003081-14-NL   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2018-003081-14-DE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2019   Phase 2   EUCTR2018-003080-56-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2018-003081-14-HR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2021   Phase 2   EUCTR2018-003081-14-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2021   Phase 2   EUCTR2018-003080-56-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      -   Phase 2   EUCTR2018-003081-14-CZ   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   SCS Boehringer Ingelheim Comm. V
      -   Phase 2   EUCTR2018-003081-14-BE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
BI655130   
   Boehringer Ingelheim
      2016   Phase 1   NCT02978690   France;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;Tunisia;
Brodalumab   
   Kyowa Hakko Kirin Co., Ltd.
      2014   Phase 3   JPRN-JapicCTI-142430   -
      2013   Phase 3   JPRN-JapicCTI-132057   -
Brodalumab 210mg SC   
   Kyowa Kirin Co., Ltd.
      2016   Phase 4   NCT04183881   Japan;
CNTO1959   
   JANSSEN CILAG INTERNATIONAL NV
      2019   Phase 3   EUCTR2018-003206-58-IT   France;Germany;Italy;Spain;United Kingdom;
   Janssen-Cilag International N.V.
      2019   Phase 3   EUCTR2018-003206-58-GB   France;Germany;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-003206-58-FR   France;Germany;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-003206-58-ES   France;Germany;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-003206-58-DE   France;Germany;Italy;Spain;United Kingdom;
Calcitriol   
   Probiodrug AG
      2007   -   EUCTR2006-005344-83-DE   Germany;
Efalizumab   
   Technische Universität Dresden
      2007   -   EUCTR2007-003922-70-DE   Germany;
Guselkumab   
   Janssen Pharmaceutical K.K.
      2015   Phase 3   NCT02343744   Japan;
   Janssen-Cilag Ltd.
      2019   Phase 3   NCT03998683   France;Germany;Italy;Spain;United Kingdom;
Infliximab   
   TOYAMA SATOSHI
      2018   -   JPRN-jRCTs031180367   Japan;
   The University of Tokyo Hospital
      2017   -   JPRN-UMIN000027208   Japan;
Infliximab [infliximab biosimilar 3]   
   Pfizer
      2019   -   NCT03885089   Japan;
Ixekizumab   
   Eli Lilly and Company
      2019   Phase 4   NCT03942042   Japan;
KHK4827   
   Kyowa Hakko Kirin Co., Ltd.
      2014   Phase 3   JPRN-JapicCTI-142430   -
      2013   Phase 3   JPRN-JapicCTI-132057   -
   Kyowa Hakko Kirin Company, Limited
      2013   Phase 3   NCT01782937   Japan;
KHK4827 140mg SC   
   Kyowa Kirin Co., Ltd.
      2014   Phase 3   NCT02052609   Japan;
KHK4827 210mg SC   
   Kyowa Kirin Co., Ltd.
      2014   Phase 3   NCT02052609   Japan;
LY3074828   
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-JapicCTI-184065   Japan, Asia except Japan, North America, South America, Europe, Oceania;
MONOCLONAL ANTIBODY ANTI-IGG1   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2018-003081-14-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2018-003081-14-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2018-003081-14-GR   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2018-003080-56-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim España, S.A.
      2020   Phase 2   EUCTR2018-003081-14-ES   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim France
      2020   Phase 2   EUCTR2018-003081-14-FR   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
      2019   Phase 3   EUCTR2018-003080-56-FR   Australia;China;France;Germany;Greece;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
      2019   Phase 2   EUCTR2017-004231-37-FR   France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
   Boehringer Ingelheim Netherlands BV
      2020   Phase 2   EUCTR2018-003081-14-NL   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2018-003081-14-DE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2019   Phase 2   EUCTR2018-003080-56-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2018-003081-14-HR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2021   Phase 2   EUCTR2018-003081-14-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2021   Phase 2   EUCTR2018-003080-56-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      -   Phase 2   EUCTR2018-003081-14-CZ   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   SCS Boehringer Ingelheim Comm. V
      -   Phase 2   EUCTR2018-003081-14-BE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
Melatonin   
   Department of Dermatology, Children's Hospital of Chongqing Medical University
      2021   Phase 0   ChiCTR2100044690   China;
Mirikizumab   
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-JapicCTI-184065   Japan, Asia except Japan, North America, South America, Europe, Oceania;
Oxymatrine   
   General Hospital of Ningxia Medical University
      2018   Phase 0   ChiCTR2100043193   China;
P32/98   
   Probiodrug AG
      2007   -   EUCTR2006-005344-83-DE   Germany;
Placebo   
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-JapicCTI-184065   Japan, Asia except Japan, North America, South America, Europe, Oceania;
Raptiva   
   Technische Universität Dresden
      2007   -   EUCTR2007-003922-70-DE   Germany;
Risankizumab   
   AbbVie
      2017   Phase 3   NCT03022045   Japan;
Secukinumab   
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-JapicCTI-184065   Japan, Asia except Japan, North America, South America, Europe, Oceania;
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-JapicCTI-132305   -
   Novartis Pharmaceuticals
      2013   Phase 3   NCT02008890   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
      2013   Phase 3   NCT01952015   Japan;
Secukinumab 150 mg/1 mL Solution for injection   
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-003086-34-BE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Silikis 3µg/g Salbe   
   Probiodrug AG
      2007   -   EUCTR2006-005344-83-DE   Germany;
Spesolimab   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2018-003081-14-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2018-003081-14-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim
      2022   Phase 3   NCT05239039   -
      2022   Phase 3   NCT05200247   Japan;
      2020   Phase 2   NCT04399837   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
      2020   Phase 2   JPRN-JapicCTI-205387   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
      2019   Phase 2   NCT03886246   Argentina;China;France;Germany;Japan;Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 2   NCT03782792   China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States;
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2018-003081-14-GR   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2018-003080-56-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim España, S.A.
      2020   Phase 2   EUCTR2018-003081-14-ES   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim France
      2020   Phase 2   EUCTR2018-003081-14-FR   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam;
   Boehringer Ingelheim Netherlands BV
      2020   Phase 2   EUCTR2018-003081-14-NL   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2018-003081-14-DE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2019   Phase 2   EUCTR2018-003080-56-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam;
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2018-003081-14-HR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2021   Phase 2   EUCTR2018-003081-14-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      2021   Phase 2   EUCTR2018-003080-56-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
      -   Phase 2   EUCTR2018-003081-14-CZ   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   SCS Boehringer Ingelheim Comm. V
      -   Phase 2   EUCTR2018-003081-14-BE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam;
   Yamada Nobuko
      2021   Phase 2   JPRN-jRCT2041210087   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea;Malaysia;Mexico;Netherlands;Philippines;Poland;Russia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;
TA-650   
   Mitsubishi Tanabe Pharma Corporation
      2012   Phase 3   NCT01680159   Japan;
TG   
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003542   China;
TREMFYA®   
   Janssen-Cilag International N.V.
      2019   Phase 3   EUCTR2018-003206-58-GB   France;Germany;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-003206-58-FR   France;Germany;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-003206-58-ES   France;Germany;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-003206-58-DE   France;Germany;Italy;Spain;United Kingdom;
Ustekinumab   
   Innovaderm Research Inc.
      2010   Phase 3   NCT01091051   Canada;